Safety and efficacy of ferric carboxymaltose in anaemic antenatal women: a prospective study
Background: Anemia is one of the most common nutritional deficiency disorders affecting the pregnant women, and is a worldwide problem. In India, prevalence ranges from 23.6%-61.4% and contributes to 80% of maternal mortality as a direct or indirect cause. This study aims to assess the efficacy and safety of intravenous ferric carboxymaltose in antenatal women with moderate anemia in the second and third trimester of pregnancy.Methods: Prospective clinical study; total of 100 antenatal women with moderate anemia in second and third trimester were included in the study from January 2019 to September 2019 and given 1000mg of intravenous ferric carboxymaltose injection. Efficacy was assessed by rate of improvement in hemoglobin at 3 and 6 weeks post infusion. Safety analysis was done by assessing the adverse drug reactions and fetal heart monitoring during the infusion.Results: A total 100 antenatal women with median gestational age of 28week at presentation received 1000mg of intravenous ferric carboxymaltose. There was rise in hemoglobin from 8.3gm% before injection to 11.12gm% 6 weeks post infusion, showing a mean rise of 2.8gm%. There were no reports of drug related major adverse effects in the mother or the fetus.Conclusions: From this study, ferric carboxymaltose is found to be safe and effective treatment option for anemia in pregnancy.